title: Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
authors.affiliation: Yale School of Medicine, New Haven, Connecticut.
authors.forename: Jean-Francois H
authors.initials: JF
authors.lastname: Geschwind
authors.affiliation: Yale School of Medicine, New Haven, Connecticut.
authors.forename: Julius
authors.initials: J
authors.lastname: Chapiro
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D000066491:Clinical Decision-Making; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib